weeks and patients with compensated cirrhosis were randomized 1:1 to the same regimen for either 12 or 24 weeks. Sixty patients with compensated cirrhosis were randomized to treatment for 12 weeks (n = 31) or 24 weeks (n = 29). In the 12-week arm, significant improvements were observed in biomarkers of liver injury (alanine aminotransferase: -53.7 U/L, P < 0.001; aspartate aminotransferase: -35.9 U/L, P < 0.001) and liver fibrosis (aspartate aminotransferase to platelet ratio index: -0.987, P < 0.001; fibrosis-4 index: -1.165, P < 0.001). Similar results were reported in the 24-week arm. Treatment with ombitasvir/paritaprevir/ritonavir plus RBV in hepatitis C virus genotype, 4-infected Egyptians with compensated cirrhosis resulted in improvements in certain biomarkers of liver synthetic function, injury, and fibrosis, independent of treatment duration. 
| MATERIALS AND METHODS

| Study design and participants
Trial design was described previously. 9 Briefly, AGATE-II was a One patient without cirrhosis was miscategorized as having compensated cirrhosis at the time of enrollment and was assigned to the 12-week arm.
*(ClinicalTrials.gov, NCT02247401).
1 Information Materials and Methods). All patients gave a written informed consent.
| Analyses
In this post hoc analysis, mean changes from baseline to posttreatment week 48 (PTW48) in biomarkers of liver synthetic function, liver injury, and liver fibrosis were assessed for patients with compensated cirrhosis. Markers of hepatic synthetic function were international normalized ratio (INR), albumin, and total bilirubin; markers of liver injury were alanine aminotransferase (ALT) and AST; markers of liver fibrosis were platelet count, APRI, and fibrosis-4 (FIB-4) index.
| Statistical analysis
All patients who received at least one dose of study drug were included in the analyses. Baseline was defined as the last value collected before the first dose of study drug. Change from baseline was evaluated with the Wilcoxon signed-rank test.
3 | RESULTS
| Patients
Out of 182 patients screened between November 4, 2014 and March 16, 2015, 160 patients were enrolled in the trial: 100 without cirrhosis and 60 with compensated cirrhosis (12-week arm, n = 31; 24-week arm, n = 29). Patient demographics and baseline disease characteristics for patients with compensated cirrhosis, who are included in this subanalysis, were reported previously. 9 There were no clinically relevant differences in patient demographics or baseline disease characteristics between the two treatment arms (Table 1 ). In the 12-week arm, there was one (3%) patient without cirrhosis (Metavir fibrosis stage F3) who was miscategorized as having compensated cirrhosis.
| Liver synthetic function
At PTW48, there were statistically significant improvements compared with baseline in mean total bilirubin for the 24-week arm, although the baseline and PTW48 values for both treatment arms were within normal limits ( Figure 1A ). Mean albumin was within normal limits at baseline and PTW48 for both treatment arms ( Figure 1B) . Mean INR increased slightly from baseline for both the 12-and 24-week treatment arms but remained near the 1.1 normal range ( Figure 1C ).
| Liver injury
At PTW48, there was an over threefold reduction in ALT ( Figure 2A) and an approximately 2.5-fold reduction in AST ( Figure 2B ) in both the 12-and 24-week treatment arms. For both arms, the mean ALT
and AST values were elevated at baseline and improved to values within normal limits at PTW48.
| Liver fibrosis
Treatment with OBV/PTV/r+RBV resulted in statistically significant improvements at PTW48 in APRI ( Figure 3A ) and FIB-4 scores Europe/North America, 12 and ONYX-II, which evaluated 12-week treatment in GT1b-infected patients from Asia. 13 Post hoc assessments of these trials suggested improvements in several biomarkers of liver function up to PTW48. 12, 13 In a pooled analysis of the TURQUOISE-II and TOPAZ-II studies, patients with compensated cirrhosis treated with OBV/PTV/r+dasabuvir+RBV showed significant fibrosis regression, as measured by FibroTest, from baseline to PTW12. 14 This effect was reported both in patients who achieved SVR12 and in those who did not, although patients who did achieve SVR12 had a statistically greater reduction in fibrosis.
14 A limitation of this analysis was the small sample size of the study, so these results must be confirmed with larger studies. In addition, trials using histologic assessments of fibrosis are needed to confirm these results and to account for any effect that necroinflammation may have on fibrosis indices and elasticity quantification. 
